B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

54.44 +1.38 (+2.59%)
Streaming Delayed Price Updated: 10:43 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
News headline image
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This... 
Via MarketMinute
News headline image
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026 ↗
Via Stocktwits
Bristol Myers Announces Positive Outcomes From Multiple Myeloma Late-Stage Study ↗
Via Stocktwits
J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Study ↗
Via Stocktwits
News headline image
Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst ↗
President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly... 
Via Benzinga
Topics Government World Trade
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
From Bristol Myers Squibb
Via Business Wire
News headline image
The Smartest Dividend Stock to Buy With $1,000 Right Now ↗
Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗
Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients ↗
Bristol Myers Squibb reported positive Phase 3 results for iberdomide in multiple myeloma; analysts eye CELMoDs as key to future growth. 
Via Benzinga
News headline image
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Reason to Buy Bristol Myers Squibb Stock ↗
Find out why investors seeking passive income want shares of this dividend payer in their portfolio. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
News headline image
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Replimune Stock Plummeted by Almost 40% Today ↗
The fate of a once-promising cancer treatment now looks uncertain at best. 
Via The Motley Fool
News headline image
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis. 
Via Benzinga
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Great High-Yield Dividend Stocks to Buy in September ↗
Quality yields above 6% from three very different market sectors. 
Via The Motley Fool
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability ↗
Bristol-Myers Squibb (BMY) offers a compelling 5.22% dividend yield with a strong history of growth, backed by high profitability and an attractive valuation. 
Via Chartmill
News headline image
The Specter of Stagflation: A Looming Threat to Global Markets
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
News headline image
The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now ↗
With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward. 
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy ↗
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.